GOLD SWAP Share Price OTC Bulletin Board
Equities
GDSW
US38074W1009
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
04-23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
04-10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Sales 2024 * | 72K 5.75M | Sales 2025 * | 72K 5.75M | Capitalization | 5.26M 420M |
---|---|---|---|---|---|
Net income 2024 * | -4M -319M | Net income 2025 * | -8M -639M | EV / Sales 2024 * | 73.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 73.1 x |
P/E ratio 2024 * |
-3.3
x | P/E ratio 2025 * |
-2.64
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.01% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 12/07/10 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 26/09/22 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 31/08/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 12/07/10 |
Wayne Linsley
BRD | Director/Board Member | 67 | 15/01/20 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 30/09/20 |
1st Jan change | Capi. | |
---|---|---|
-4.49% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- SILO Stock
- GDSW Stock